Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 7/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512439 | 0.80 | NPC1 (0.50) | ADORA3ADORA1ADORA2ANPC1RAB9A | |
| SCHEMBL14941820 | 0.78 | RAB9A (0.43) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL21023293 | 0.76 | ADORA2A (0.55) | ADORA3ADORA1ADORA2ANPC1RAB9A | |
| SCHEMBL28395491 | 0.76 | NPC1 (0.57) | ADORA3ADORA1ADORA2ANPC1RAB9A | |
| SCHEMBL1558294 | 0.75 | BCHE (0.36) | ADORA3ADORA1ADORA2ANPC1RAB9A | |
| SCHEMBL9265475 | 0.74 | KDM4E (0.36) | ADORA3ADORA1ADORA2ANPC1RAB9A | |
| SCHEMBL29614829 | 0.73 | NPC1 (0.63) | ADORA3ADORA1ADORA2ANPC1RAB9A | |
| SCHEMBL29942654 | 0.73 | NPC1 (0.63) | ADORA3ADORA1ADORA2ANPC1RAB9A | |
| SCHEMBL29966674 | 0.73 | NPC1 (0.63) | ADORA3ADORA1ADORA2ANPC1RAB9A | |
| SCHEMBL3076524 | 0.73 | NPC1 (0.63) | ADORA3ADORA1ADORA2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117529202-A | Organometallic compound, light-emitting device, electronic apparatus, and electronic device | 三星显示有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-115701262-A | Organic light emitting device | 三星电子株式会社 | 2023-02-07 | — | — | CN | disclosed |
| US-9255091-B2 | Benzothiazole-based pyridinium compounds | THE UNIVERSITY OF MONTANA (US) | 2016-02-09 | — | — | US | disclosed |
| EP-2948129-A1 | THERAPEUTIC COMPOUNDS | Wintermute Biomedical LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150259336-A1 | Benzothiazole-based Pyridinium Compounds for the Treatment of Neurodegenerative Diseases or Nerve Agent Exposure | THE UNIVERSITY OF MONTANA (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2014117056-A1 | THERAPEUTIC COMPOUNDS | WINTERMUTE BIOMEDICAL, LLC (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20090023728-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6147051-A | ANTIISCHEMIC AGENT | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-4902800-A | USED AS ANTIINFLAMMATORY AGENTS AND IN TREATMENT OF DISEASE STATES INVOLVING ENZYMATIC TISSUE DESTRUCTION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259336-A1 | Benzothiazole-based Pyridinium Compounds for the Treatment of Neurodegenerative Diseases or Nerve Agent Exposure | BCHE, ACHE, BACE1 | ADORA3 1875/4885ADORA1 1327/4885ADORA2A 2442/4885 |
| US-20090023728-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparations Thereof and Uses Thereof | OPRD1, QDPR, RECQL | ADORA3 381/4885ADORA1 537/4885ADORA2A 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.